

Industry

Biotechnology:
Inflammation & Immunology

Management

CEO: Erika Smith, MBA
- Over 30 Years Life Sciences BD
- 2x CEO
- Successful Exits as Operator and Investor

CSO: George Maynard, PhD
- Over 30 Years Med Chem
- Led Candidates Through Phase II

Advisory Board

Scientific Co-Founder:
Yingqun Huang, MD, PhD
- Professor, OB/GYN, Yale School of Medicine

Drug Discovery & Development:
James Winkler, PhD
- Founding CSO of Arvinas
- Expert in Protein Degradation
Epigenetics & Oncology:
Ho Man Chan, PhD
- Small Molecule Bioscience, Epigenetics, Oncology at AZ

Clinical Strategy
Hugh Taylor, MD
- Clinical Lead Investigator for Endometriosis Drug at AbbVie
- Chair, OB/GYN, Yale New Haven Hospital

Intellectual Property
Composition of Matter & Methods of Use through 2043
- Licensed from Yale University
- Strategic Expansion Support from Greenberg Traurig LLP

Legal
Shipman & Goodwin LLP

Mission

We are committed to developing a first-in-class, oral drug that disrupts the inflammatory disease micro-environment associated with chronic inflammation and cancer

Science

- Disease microenvironments exhibit increased levels of pathogenic macrophages which promote inflammation upregulating a key protein TET3.
- EpTET leverages a natural degradation pathways to selectively remove TET3. The lead compound is orally available with a positive safety profile.
- This enables the removal of pathogenic macrophages, thereby decreasing inflammation without suppressing overall immunity.

Indications & Market Opportunity

Targeting TET3 over-expressing pathogenic macrophages is under investigation for several diseases characterized by chronic inflammation and immunological dysfunction. The global inflammation & immunology market value is over \$100B. **TET3 is a validated target across the following indications with genetic expression, knockout, and pre-clinical models results published in key journals with multiple paths to clinic.**

Endometriosis: Heightened numbers of TET3 over-expressing macrophages in endometriotic lesions promote lesion growth, vascularization, and innervation, playing a key role in disease progression and pain. The global endometriosis treatment market was valued at \$1.76 billion in 2024.

Obesity Related Disease: Pathogenic macrophages play an important role in the progression of metabolic dysfunction-associated steatohepatitis (MASH). The MASH market was valued at approximately \$1.8B in 2023.

Oncology: TET3 overexpressing macrophages are important for tumor survival and growth in a model of non-small cell lung cancer (NSCLC). The global market for NSCLC therapeutics was valued at \$20B in 2023.

Competitive Advantage

The company's technology leverages several key competitive advantages in addition to its team and IP:

- Current treatments (steroids, biologics) suppress inflammation with side effects or target inflammation mediators rather than the root cause
- Novel protein target (TET3) over-expressed across multiple diseases
- Selective approach with oral availability and excellent safety profile
- We address one of the first responders of the immune system (macrophages) whose malfunctioning contributes to inflammatory disease

Example Exit (Endometriosis)

